Free database of papers and journals

Results 1 to 20 of 29 articles found

The efficacy and safety of tadalafil: an update

BJU International (3.5 149), 93, 1276-1281.

Tadalafil: a new treatment for erectile dysfunction

BJU International (3.5 149), 91, 466-468.

Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies

BJU International (3.5 149), 103, 1212-1217.

Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction

BJU International (3.5 149), 94, 871-877.

Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials

BJU International (3.5 149), 96, 857-863.

cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil

BJU International (3.5 149), 0, 071115142947001-???.

Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms

BJU International (3.5 149), 123, 124-129.

Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection

BJU International (3.5 149), 0, 070921231855003-???.

Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial

BJU International (3.5 149), 125, 718-724.

The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study

BJU International (3.5 149), 99, 121-126.

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

BJU International (3.5 149), 105, 502-507.

Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves

BJU International (3.5 149), 110, E259-E266.

The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients

BJU International (3.5 149), 103, 506-514.

Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil

BJU International (3.5 149), 109, 1060-1067.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study

BJU International (3.5 149), 107, 1110-1116.

An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease

BJU International (3.5 149), 99, 387-393.

Effect of tadalafil 5 mg on post-micturition dribble in men with lower urinary tract symptoms: a multicentre, double-blind, randomized, placebo-controlled trial

BJU International (3.5 149), 124, 862-869.

Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment

BJU International (3.5 149), 118, 153-160.

Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction

BJU International (3.5 149), , n/a-n/a.

Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian ‘Treatment of Erectile Dysfunction’ observational study

BJU International (3.5 149), 98, 623-629.
Anatomy of Results
The left numbers are the publication year, and the number of citations (hyperlink to the full citation report of the paper)
paranthesis after the journal provides its impact factor.
paranthesis after the author indicates the number of publications and Author's Impact Factor